Marksans Pharma Limited (NSE: MARKSANS)

Market Cap	119.22B
Revenue (ttm)	22.68B
Net Income (ttm)	3.34B
Shares Out	453.16M
EPS (ttm)	7.36
PE Ratio	35.75
Forward PE	30.83
Dividend	0.60 (0.23%)
Ex-Dividend Date	Sep 17, 2024

Volume	10,747,936
Open	268.05
Previous Close	259.00
Day's Range	261.75 - 278.70
52-Week Range	97.45 - 278.70
Beta	1.63
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 1,141
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MARKSANS

Financial Performance

In 2023, MARKSANS's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.